Antibody-based delivery of tumor necrosis factor (L19-TNF&#945;) and interleukin-2 (L19-IL2) to tumor-associated blood vessels has potent immunological and anticancer activity in the syngeneic J558L BALB/c myeloma model.

Menssen, Hans D; Harnack, Ulf; Erben, Ulrike; Neri, Dario; Hirsch, Burkhard; Dürkop, Horst

Antibody-based delivery of tumor necrosis factor (L19-TNFα) and interleukin-2 (L19-IL2) to tumor-associated blood vessels has potent immunological and anticancer activity in the syngeneic J558L BALB/c myeloma model.

Menssen, Hans D; Harnack, Ulf; Erben, Ulrike; Neri, Dario; Hirsch, Burkhard; Dürkop, Horst.

Afiliação

Menssen HD; Division of Hematology and Oncology, Campus Benjamin Franklin, Department of Medicine, Charité-Universitätsmedizin Berlin, Hindenburgdamm 30, 12203, Berlin, Germany. hans_dietrich.menssen@charite.de.
Harnack U; Division of Oncology and Hematology, Campus Mitte, Department of Medicine, Charité-Universitätsmedizin Berlin, Charité-Platz 1, 10117, Berlin, Germany.
Erben U; Division of Gastroenterology, Infectious Diseases and Rheumatology, Medical Department, Campus Benjamin Franklin, Charité-Universitätsmedizin Berlin, Hindenburgdamm 30, 12203, Berlin, Germany.
Neri D; Department of Chemistry and Applied Biosciences, Institute of Pharmaceutical Sciences, ETH Zurich, Wolfgang-Pauli-Str. 10, 8093, Zurich, Switzerland.
Hirsch B; Department of Pathology at Campus Benjamin Franklin, Campus Mitte, Institute of Pathology, Charité-Universitätsmedizin Berlin, Virchowweg 15, 10117, Berlin, Germany.
Dürkop H; Department of Medicine, Campus Mitte, Institute of Pathology, Charité-Universitätsmedizin Berlin, Virchowweg 15, 10117, Berlin, Germany.

J Cancer Res Clin Oncol ; 144(3): 499-507, 2018 Mar.

Article em En | MEDLINE | ID: mdl-29327244

Assuntos

Inibidores da Angiogênese/uso terapêutico; Anticorpos Monoclonais/uso terapêutico; Imunoterapia/métodos; Interleucina-2/uso terapêutico; Mieloma Múltiplo/terapia; Neovascularização Patológica/tratamento farmacológico; Fator de Necrose Tumoral alfa/uso terapêutico; Animais; Vacinas Anticâncer/uso terapêutico; Linhagem Celular Tumoral; Sistemas de Liberação de Medicamentos; Feminino; Imunotoxinas/uso terapêutico; Camundongos; Camundongos Endogâmicos BALB C; Mieloma Múltiplo/imunologia; Mieloma Múltiplo/patologia; Linfócitos T Reguladores/efeitos dos fármacos; Linfócitos T Reguladores/imunologia; Transplante Isogênico

Palavras-chave

IL-2; J558L myeloma; PD-1; PD-L1; TNF-α, immune modulation of tumor microenvironment; Targeted immunocytokines

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Interleucina-2 / Fator de Necrose Tumoral alfa / Inibidores da Angiogênese / Imunoterapia / Anticorpos Monoclonais / Mieloma Múltiplo / Neovascularização Patológica Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Animals Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google